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Objectives: Stavudine is widely used in Thailand and is associated with mitochondrial toxicity. Here,
we evaluated the effect of switching from stavudine/didanosine to tenofovir/lamivudine on measures of
metabolic and mitochondrial toxicity in Thai patients.
Methods: Thirty-five Thai patients with full HIV RNA suppression were switched from stavudine/
didanosine to tenofovir/lamivudine while receiving saquinavir/ritonavir 1600/100 mg once daily. Patients
were assessed at the time of switch and 24 and 48 weeks after for lipids, liver enzymes, lactate, mito-
chondrial DNA content and limb/total fat mass by dual energy X-ray absorptiometry (DEXA) scanning.
Results: Forty-eight weeks after the switch, there were significant reductions in lipids and lactate, but
no change in liver enzymes. There was reversal of lipoatrophy, as shown by rises in limb fat mass
(10.38 kg, P 5 0.006) and total fat mass (10.69 kg, P 5 0.02) on DEXA scan. Patients perceived weight
improvement, but did not report reversal of lipoatrophy of individual body parts. The mitochondrial
DNA/nuclear DNA ratio rose (11.06, P < 0.0001).
Conclusions: After the nucleoside reverse transcriptase inhibitor switch, reversal of mitochondrial tox-
icity was consistent with switch studies of mainly Caucasian patients, although the peripheral mono-
nuclear cell mitochondrial DNA rise exceeded previous reports.
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Introduction
As highly active antiretroviral therapy (HAART) is often life
long, minimizing toxicity is a priority. Lipoatrophy, a condition
characterized by the atrophy of adipose tissue on extremities and
the face, along with accumulation of visceral fat, develops in
many patients treated with a combination of protease inhibitor
and nucleoside reverse transcriptase inhibitors (NRTIs).1
Mitochondrial toxicity accompanied by decreased mitochondrial
DNA, increased serum lactate and fat atrophy has been associ-
ated with NRTIs in general and stavudine in particular. Adipose
tissue mitochondrial DNA depletion is an important determinant
of stavudine-induced lipoatrophy pathogenesis. These changes
are partially reversed when stavudine is stopped.2,3 However,
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this relationship has not been established for peripheral blood
mononuclear cell (PBMC) mitochondrial DNA, where it appears
that didanosine is the dominant treatment-related determinant of
mitochondrial DNA depletion.4 – 6 Mitochondrial DNA changes
in PBMCs do not appear to predict the mitochondrial DNA
changes in tissue5,7 and can vary regardless of NRTI use.4
In randomized Phase 3 trials, first-line treatment with tenofo-
vir leads to lower rates of clinically diagnosed lipoatrophy and
lipid elevations, relative to either stavudine8 or zidovudine.9
Previous studies have shown improvements in lipoatrophy and
lipid parameters after a switch to either tenofovir or abacavir.10
In the A5005s study, a sub-study of ACTG 384, patients given
first-line stavudine/didanosine-based HAART showed greater
rises in lipid parameters and a higher incidence of lipoatrophy,
relative to those given zidovudine/lamivudine.11 There is also
evidence that higher stavudine doses may increase the incidence
of lipoatrophy.12
Staccato was a randomized trial of intermittent versus con-
tinuous antiretroviral treatment. Prior to randomization,
antiretroviral-naive Thai patients with CD4 counts of 200–
350 cells/mm3 were given first-line treatment with stavudine/
didanosine (stavudine 30 or 40 mg, didanosine 250 or 400 mg
based on weight below or above 60 kg) plus saquinavir/ritonavir
(1600/100 mg once daily), until HIV RNA was suppressed
below 50 copies/mL and CD4 count was above 350 cells/mm3.
They were then randomized to either continuous or interrupted
treatment.13,14 During the Staccato trial, the NRTI backbone
for Thai patients was switched from stavudine/didanosine to
tenofovir/lamivudine according to new treatment guidelines,
although saquinavir/ritonavir treatment was maintained. This
offered the opportunity to study the effect of this change on
measures of metabolic and mitochondrial toxicity.
Methods
This substudy included 35 patients in the continuous treatment arm,
who were consecutively recruited at one Thai centre. We measured
changes in mitochondrial and metabolic toxicity before and after
switching from stavudine/didanosine to tenofovir/lamivudine.
Patients were assessed at the time of switch from stavudine/
didanosine to tenofovir/lamivudine (week 0) and at 24 and 48
weeks after the switch. The patients were evaluated for lipids
[triglycerides, total cholesterol, high-density lipoprotein (HDL),
low-density lipoprotein (LDL) and triglycerides], liver enzymes
[alanine transaminase (ALT)] and lactate. At weeks 0, 24 and 48,
patients completed a lipodystrophy questionnaire, where they
answered questions about change in various body parts in the pre-
vious 6 months, on a 7-point scale with the mid value representing
normal and the values on either side representing mildly, moderately
or much thinner or fatter. Patients were also asked whether their
weight had increased, decreased or stayed the same compared with
the previous 6 months. Mitochondrial DNA was measured from
PBMCs in all 35 patients, as described previously15,16 and in
blinded fashion. In addition, lipoatrophy was assessed by dual
energy X-ray absorptiometry (DEXA) scanning at weeks 0 and 48
in 22 patients. During the trial, two patients became pregnant. One
patient, with an approximate break from tenofovir of 2 months with
substitution to zidovudine until premature termination of pregnancy,
and then switch back to tenofovir, was kept in the analysis. The
other patient stopped tenofovir with zidovudine substitution after
week 24, so week 48 results were deleted from the data set.
Differences over time were assessed by the measured change in
scores from baseline to week 24 and week 48. Results are expressed
as median [interquartile range (IQR)]. For analysis of the lipodystro-
phy questionnaire, we attributed a score to each answer an individ-
ual patient made and summed the difference from scores from
baseline to week 48. A formal comparison of the cumulative change
in score from baseline was made using the Wilcoxon rank sum test.
The Staccato protocol was accepted by the local Ethics
Committees from the different participating centres, and written
informed consent was obtained from each participant. The Staccato
study is registered at ClinicalTrials.gov with the identifier
NCT00113126.
Results
Of the 35 patients in the substudy, 22 (63%) were female and 13
(37%) were male. The median age was 34 (IQR 31–39) years
and the median weight was 55 (IQR 49–61.5) kg. The median
baseline CD4 count was 548 (IQR 483–682) cells/mm3. The
median time on stavudine/didanosine was 86 (IQR 69–182)
weeks. The baseline metabolic parameters are shown in Table 1.
The median values of triglycerides, cholesterol and HDL were
mildly abnormal. The median mitochondrial DNA/nuclear DNA
ratio was 1.22 (IQR 0.85–1.55), and the median limb and total
fat masses were 5.1 (IQR 2.7–7.2) and 10.2 (IQR 8.2–13.7) kg,
respectively. Twenty-eight patients had an assessment of lipody-
strophy at the time of switching to tenofovir, and, of these, 15
(54%) had lipodystrophy. Nine (26%) patients experienced per-
ipheral neuropathy at the time of starting tenofovir. The baseline
characteristics (gender, age, weight, CD4 and lipids) of the
patients in this substudy did not differ significantly from the
other 94 patients in Staccato at our centre.
During the 48 weeks after the switch to tenofovir/lamivudine,
the median CD4 count rose by 40 cells (P ¼ 0.009). HIV RNA
levels were suppressed below 50 copies/mL in 94% of the patients
at baseline, and this suppression rate was maintained at week 48.
After the switch from stavudine/didanosine to tenofovir/
lamivudine, the mitochondrial DNA content (expressed as the
relative mitochondrial DNA/nuclear DNA ratio) rose signifi-
cantly to a larger extent than reported in other studies involving
Table 1. Median metabolic parameters before switching from
stavudine/didanosine to tenofovir/lamivudine
Baseline variables Median (IQR)
Triglycerides, mg/dL 147 (97–327)
Cholesterol, mg/dL 212 (192–233)
HDL, mg/dL 59 (48–70)
LDL, mg/dL 112 (93–127)
ALT, U/L 28 (19–50)
Lactate, mmol/L 1.5 (1.1–2.3)
Mitochondrial DNA/nuclear DNA ratio 1.22 (0.85–1.55)
Limb fat mass, kg 5.1 (2.7–7.2)
Total fat mass, kg 10.2 (8.2–13.7)
The upper limits of normal are as follows: triglycerides (140 mg/dL),
cholesterol (250 mg/dL), LDL (160 mg/dL), ALT (31 mg/dL), lactate
(2.4 mmol/L). HDL below 75 mg/dL is abnormal.
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patients who either discontinued15 or changed dideoxy NRTI to
tenofovir.17 There were significant reductions in the levels of the
lipid parameters (triglycerides, total cholesterol, HDL and LDL)
measured at both weeks 24 and 48 (Table 2), with the exception
of LDL at week 48. Levels of ALT did not change significantly
during the 48 week trial interval, but there were significant
reductions in lactate levels. There was evidence of reversal of
lipoatrophy on DEXA scan, as shown by significant rises in
limb fat mass (þ0.38 kg, P ¼ 0.006) and total fat mass
(þ0.69 kg, P ¼ 0.02) (Table 2). Patients’ own subjective assess-
ment by lipodystrophy questionnaire showed the following
median (IQR) cumulative change scores: face¼0 (21 to 1),
abdomen¼0 (0 to 1), legs¼0 (0 to 0), arms¼0 (21 to 0),
thighs¼0 (0 to 0) and back and base of the neck¼0 (0 to 0).
None of these changes was significant. The median cumulative
change in patient perception of overall weight was 1 (0–3)
(P , 0.0001). There was no significant correlation between
changes in mitochondrial DNA and improvement of lipid con-
centrations or fat mass at week 48.
Discussion
Our study showed that switching from stavudine/didanosine to
tenofovir/lamivudine resulted in significant reductions in lipids
and lactate and rises in limb and total fat masses and mitochon-
drial DNA/nuclear DNA ratio. Patients perceived an overall
weight gain but not improvement of lipoatrophy.
The improvements in lipids and fat mass in our study are
similar to those seen in the GS903, MITOX and RAVE studies
of the switch from stavudine to either tenofovir or abaca-
vir.10,18,19 It is not surprising that the patients did not perceive a
significant improvement in body shape as clinical lipoatrophy
resolves slowly following treatment modification. The rise in
PBMC mitochondrial DNA after stopping stavudine/didanosine
suggests that this regimen caused mitochondrial depletion in
PBMC. Whether this effect was due to stavudine or didanosine
is unclear. Cherry et al.5 found evidence for didanosine-
associated PBMC mitochondrial DNA depletion, but not for sta-
vudine. The rise in mitochondrial DNA was not correlated with
other metabolic improvements in our study supporting the exist-
ing evidence which questions the reliability of PBMC mitochon-
drial DNA as a marker of lipoatrophy risk.4,5
HAART regimens containing stavudine are still widely used
in Southeast Asia and sub-Saharan Africa, owing to low cost
and availability of fixed-dose combinations.20 Minimum costs of
HAART in least developed countries are $339 per person-year
for the combination of tenofovir, lamivudine and efavirenz
versus $139 per person-year for co-formulated stavudine, lami-
vudine and nevirapine;21 there is a similar price difference in
Thailand. Stavudine is still used in preference to tenofovir in
Thailand as first-line treatment, due to cost pressures. Simply
starting a first-line regimen with tenofovir would lessen meta-
bolic and mitochondrial toxicity. Given the modest improvement
in our study, however, it is uncertain whether avoiding stavudine
altogether is the best practice in settings where resources are
limited if fewer people would be treated owing to the high cost
of alternative NRTIs. Other strategies would be early switch
from stavudine to tenofovir when there are any signs or symp-
toms of mitochondrial toxicity or after 1–2 years on stavudine.
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